Related Experiment Videos
Rapid initiation of gabapentin: a randomized, controlled trial.
R S Fisher1, R C Sachdeo, J Pellock
1Epilepsy Center, Stanford Medical School, CA 94305-5235, USA. rfischer@stanford.edu
Neurology
|March 29, 2001
Summary
Starting gabapentin therapy at 900 mg/day is well tolerated for epilepsy patients. This rapid initiation is as safe as a 3-day titration, with only slightly more dizziness reported.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Patient compliance is crucial for effective epilepsy pharmacotherapy.
- Simpler drug initiation regimens may improve patient adherence.
- Rapid titration of gabapentin could enhance compliance.
Purpose of the Study:
- To compare the tolerability of two gabapentin dose-initiation regimens.
- To evaluate rapid versus slow initiation of gabapentin for partial seizures.
Main Methods:
- Adult patients with partial seizures were randomized.
- Gabapentin initiation involved either a 3-day slow titration or immediate 900 mg/day rapid initiation after a placebo period.
Main Results:
- Initiating gabapentin at 900 mg/day was well tolerated and safe.
- Rapid initiation was comparable to slow titration regarding overall tolerability.
- Dizziness was the only adverse event significantly more frequent in the rapid initiation group.
Conclusions:
- Gabapentin initiation at 900 mg/day is a viable and well-tolerated option.
- Rapid initiation offers similar safety to a 3-day titration, with a manageable increase in dizziness.